Orphinic Scientific is a biopharmaceutical company. The company specializes in developing solutions for orphan diseases and other indications with significant unmet medical needs. Orphinic Scientific is currently developing over 10 products in pharmaceutical and medtech, including Tramag, an opioid analgesic, and Ambulero, a gene therapy. The company has 8 projects in the pipeline in three healthcare segments: therapeutics, medtech, and e-health. Orphinic Scientific's competencies include selecting investment targets, running clinical trials, and managing product sales to pharmaceutical companies. The founders have over 20 years of experience in drug discovery projects, clinical trials, and business development. The company is focused on expanding its presence in the US market and is open to approaches from investors, particularly US-based VC funds.
Headquarters
Ul. Postepu 21B
Warsaw; Mazowieckie;
Postal Code: 02-676
Contact Details: Purchase the Orphinic Scientific S.A. report to view the information.
Website: http://www.orphinic.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service